华润医药拟参与设立基金

Group 1 - China Resources Pharmaceutical (03320) announced a collaboration with its subsidiaries and Hanwei Huayou Shantou to establish a fund with an expected scale of RMB 500 million [1] - The fund is anticipated to focus on high-growth investments in synthetic biology, innovative drugs, and biotechnology sectors [1] - The company plans to commit a total investment of up to RMB 123 million, representing approximately 24.6% of the total fund commitment [1] - The fund is expected not to be accounted as a subsidiary of the company upon establishment [1] - Shenzhen China Resources Capital is expected to be appointed as the fund manager [1]